Fox Chase Cancer Center News

​PHILADELPHIA (March 22, 2016) — Mohan Doss, PhD, MCCPM, will receive the Outstanding Leadership Award in the field of dose-response on behalf of Scientists for Accurate Radiation Information at the 15th Annual International Conference of the International Dose-Response Society in Amherst, MA.

PHILADELPHIA (March 21, 2016) — Faculty, staff, volunteers, patients, survivors, and their families will come together as members of the Fox Chase Cancer Center team for the Colon Cancer Coalition’s Annual Get Your Rear in Gear run/walk on Sunday, April 3, 2016. The family-friendly 4-mile run, 2-mile walk, and kids fun run will take place at the Please Touch Museum in Memorial Hall.

PHILADELPHIA (March 9, 2016) – Fox Chase Cancer Center researchers recently showed that renal mass biopsy enabled accurate diagnosis of renal cell carcinoma. It can also be used to stratify patients based on disease risk — potentially minimizing the risk of over- or under-treatment in groups who could be on surveillance versus those who need surgery because of more aggressive renal tumors.

PHILADELPHIA (March 3, 2016) – March is National Colorectal Cancer Awareness Month, and Fox Chase Cancer Center strongly urges individuals to schedule their colonoscopy. Through regular screenings, colorectal cancer may be prevented or detected early, which can make treatment more successful.

PHILADELPHIA, PA (March 1, 2016) — Fox Chase Cancer Center, in partnership with its Board of Associates, will present its signature fundraising event In Vino Vita Benefit and Wine Auction on Saturday, April 9, 2016 at Vie.

PHILADELPHIA (February 22, 2016) — Eric M. Horwitz, MD, chair of radiation oncology at Fox Chase Cancer Center, has been appointed to the Pennsylvania Task Force on Prostate Cancer and Related Chronic Prostate Conditions (PCTF) by Pennsylvania Secretary of Health Dr. Karen Murphy.

PHILADELPHIA (February 22, 2016) –  Fox Chase Cancer Center – Temple Health researchers provide conclusive evidence that Bap1 is a bona fide tumor suppressor gene that strongly interacts with environmental factors to control the risk of developing malignant mesothelioma and other cancers. The findings, reported February 22^nd in Cancer Research, shed light on the recently recognized BAP1 cancer syndrome, paving the way for new early detection and therapeutic strategies for a range of highly aggressive, hard-to-treat cancers.

PHILADELPHIA (February 19, 2016) – Bone marrow transplantation has boosted survival rates from nearly zero to more than 85 percent for some blood cancers. In spite of this progress, it can produce serious side effects such as graft-versus-host disease. The clinical prognosis varies widely across individuals.